Citi analyst Laura Sutcliffe raised the firm’s price target on ResMed (RMD) to $345 from $330 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed Reaffirms 2025 Risk Profile: No Material Changes to Previously Disclosed Threats
- ResMed Inc Earnings Call Shows Profitable Growth Momentum
- ResMed price target raised to $314 from $311 at RBC Capital
- ResMed price target raised to $302 from $299 at KeyBanc
- ResMed price target raised to $265 from $260 at Stifel